MA52273A - Protéines de liaison à un antigène anti-trem2 et leurs utilisations - Google Patents

Protéines de liaison à un antigène anti-trem2 et leurs utilisations

Info

Publication number
MA52273A
MA52273A MA052273A MA52273A MA52273A MA 52273 A MA52273 A MA 52273A MA 052273 A MA052273 A MA 052273A MA 52273 A MA52273 A MA 52273A MA 52273 A MA52273 A MA 52273A
Authority
MA
Morocco
Prior art keywords
antigen binding
binding proteins
trem2 antigen
trem2
proteins
Prior art date
Application number
MA052273A
Other languages
English (en)
Inventor
Irwin Chen
Ian Driver
Ian Foltz
Susie Miki Harris
Daniel Lu
Shilpa Sambashivan
Warshaviak Dora Toledo
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MA52273A publication Critical patent/MA52273A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MA052273A 2017-04-21 2018-04-20 Protéines de liaison à un antigène anti-trem2 et leurs utilisations MA52273A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762488691P 2017-04-21 2017-04-21
US201762530753P 2017-07-10 2017-07-10
US201762580400P 2017-11-01 2017-11-01

Publications (1)

Publication Number Publication Date
MA52273A true MA52273A (fr) 2021-04-28

Family

ID=63856168

Family Applications (1)

Application Number Title Priority Date Filing Date
MA052273A MA52273A (fr) 2017-04-21 2018-04-20 Protéines de liaison à un antigène anti-trem2 et leurs utilisations

Country Status (20)

Country Link
US (2) US11186636B2 (fr)
EP (1) EP3612218A4 (fr)
JP (2) JP7252134B2 (fr)
KR (1) KR20200018778A (fr)
CN (1) CN110709100A (fr)
AU (2) AU2018254600B2 (fr)
BR (1) BR112019021991A2 (fr)
CA (1) CA3060409A1 (fr)
CL (1) CL2019003000A1 (fr)
CO (1) CO2019012998A2 (fr)
CR (2) CR20210171A (fr)
JO (1) JOP20190248A1 (fr)
MA (1) MA52273A (fr)
MX (2) MX2019012364A (fr)
PE (1) PE20200485A1 (fr)
PH (1) PH12019502356A1 (fr)
SG (1) SG11201909646TA (fr)
TW (2) TWI812619B (fr)
UY (1) UY37698A (fr)
WO (1) WO2018195506A1 (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL279606B (en) 2014-08-08 2022-08-01 Alector Llc Anti-trem2 antibodies and methods of using them
JOP20190248A1 (ar) 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
PE20200148A1 (es) * 2017-08-03 2020-01-17 Alector Llc Anticuerpos anti-trem2 y metodos para utilizarlos
UY38407A (es) 2018-10-15 2020-05-29 Novartis Ag Anticuerpos estabilizadores de trem2
MA54296A (fr) 2018-11-26 2021-10-06 Denali Therapeutics Inc Procédés de traitement du métabolisme lipidique dérégulé
US20220127356A1 (en) * 2018-12-10 2022-04-28 Mor Research Applications Trem2 antibodies and uses thereof
MA54880A (fr) * 2019-02-01 2021-12-08 Avrobio Inc Compositions et procédés de traitement de troubles neurocognitifs
WO2020172457A1 (fr) 2019-02-20 2020-08-27 Denali Therapeutics Inc. Anticorps anti-trem2 et leurs procédés d'utilisation
WO2020194317A1 (fr) 2019-03-28 2020-10-01 Yeda Research And Development Co. Ltd. Méthode de traitement de troubles liés aux lipides
US20220267444A1 (en) * 2019-08-02 2022-08-25 CTTQ-Akeso (ShangHai) Biomed. Tech. Co., Ltd. Anti-pd-1 antibody and medical use thereof
JP2023512450A (ja) 2020-01-13 2023-03-27 デナリ セラピューティクス インコーポレイテッド 抗ｔｒｅｍ２抗体及びその使用方法
TW202128771A (zh) * 2020-01-13 2021-08-01 美商戴納立製藥公司 抗trem2 抗體及其使用方法
US20230159637A1 (en) 2020-02-24 2023-05-25 Alector Llc Methods of use of anti-trem2 antibodies
WO2021203030A2 (fr) 2020-04-03 2021-10-07 Alector Llc Procédés d'utilisation d'anticorps anti-trem2
CA3190581A1 (fr) * 2020-08-05 2022-02-10 Vigil Neuroscience, Inc. Traitement de maladies associees au dysfonctionnement du recepteur de facteur 1 de stimulation des colonies au moyen d'agonistes de trem2
AU2021392813A1 (en) * 2020-12-04 2023-06-29 Vigil Neuroscience, Inc. Treatment of diseases related to atp-binding cassette transporter 1 dysfunction using trem2 agonists
WO2023047100A1 (fr) * 2021-09-21 2023-03-30 Quell Therapeutics Ltd Récepteur antigénique chimérique anti-trem2
TW202330614A (zh) * 2021-11-22 2023-08-01 美商維佳神經科學有限公司 抗ｔｒｅｍ２抗體及其用途
AU2022413364A1 (en) 2021-12-17 2024-07-25 Denali Therapeutics Inc. Polypeptide engineering, libraries, and engineered cd98 heavy chain and transferrin receptor binding polypeptides
IL314896A (en) 2022-02-23 2024-10-01 Alector Llc Methods for using anti-TREM2 antibodies
WO2023192288A1 (fr) 2022-03-28 2023-10-05 Denali Therapeutics Inc. Molécules de liaison anti-trem2 monovalentes et leurs procédés d'utilisation
WO2023192282A1 (fr) 2022-03-28 2023-10-05 Denali Therapeutics Inc. Méthodes de traitement de l'hypométabolisme du glucose cérébral
WO2024040194A1 (fr) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditionnement pour l'ingénierie de cellules immunitaires in vivo
WO2024052343A1 (fr) 2022-09-06 2024-03-14 Institut National de la Santé et de la Recherche Médicale Agonistes de trem-2 pour le traitement du syndrome de marfan
CN118420764A (zh) * 2024-04-02 2024-08-02 上海宏成药业有限公司 抗trem2抗体及其用途

Family Cites Families (237)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
WO1990005183A1 (fr) 1988-10-31 1990-05-17 Immunex Corporation Recepteurs d'interleukine-4
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US6713610B1 (en) 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
EP1690935A3 (fr) 1990-01-12 2008-07-30 Abgenix, Inc. Génération d'anticorps xenogéniques
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
AU651596B2 (en) 1990-06-05 1994-07-28 Immunex Corporation Type II interleukin-1 receptors
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
JPH06508035A (ja) 1991-06-14 1994-09-14 ディーエヌエックス　コーポレーション トランスジェニックブタにおけるヒトヘモグロビンの生産
EP0593592B1 (fr) 1991-07-08 1998-03-25 The University Of Massachusetts At Amherst Copolymere en masse segmentee a cristaux liquides thermotropiques
EP1136556B1 (fr) 1991-11-25 2005-06-08 Enzon, Inc. Procédé pour produire de protéines multivalents de fixation de l'antigène
WO1994002602A1 (fr) 1992-07-24 1994-02-03 Cell Genesys, Inc. Production d'anticorps xenogeniques
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
EP1978033A3 (fr) 1995-04-27 2008-12-24 Amgen Fremont Inc. Anticorps humains dérivés à partir de xénosouris immunisée
WO1997034631A1 (fr) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Domaines analogues a l'immunoglobuline a demi-vies prolongees
ATE549918T1 (de) 1996-12-03 2012-04-15 Amgen Fremont Inc Menschliche antikörper, die ausdrücklich menschliches tnf alpha binden
CA2284131A1 (fr) 1997-03-07 1998-09-11 Human Genome Sciences, Inc. 70 proteines humaines secretees
US6878687B1 (en) 1997-03-07 2005-04-12 Human Genome Sciences, Inc. Protein HMAAD57
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
WO2000000610A2 (fr) 1998-06-26 2000-01-06 Incyte Pharmaceuticals, Inc. Proteines contenant un peptide signal humain
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
AUPQ873300A0 (en) 2000-07-12 2000-08-03 Medvet Science Pty. Ltd. A binding motif of a receptor (2)
AU4761601A (en) 2000-04-11 2001-10-23 Genentech Inc Multivalent antibodies and uses therefor
CA2431177C (fr) 2000-12-08 2015-04-14 Baylor College Of Medicine Variant d'epissage de trem-1 utile pour modifier des reactions immunitaires
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
CA2342376C (fr) 2001-03-20 2013-11-12 Marco Colonna Nouveau recepteur trem (recepteur activateur exprime dans les cellules myeloides) et ses utilisations
US8981061B2 (en) 2001-03-20 2015-03-17 Novo Nordisk A/S Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
US8231878B2 (en) 2001-03-20 2012-07-31 Cosmo Research & Development S.P.A. Receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
ATE454137T1 (de) 2001-07-25 2010-01-15 Facet Biotech Corp Stabile lyophilisierte pharmazeutische formulierung des igg-antikörpers daclizumab
MXPA04003291A (es) 2001-10-12 2004-07-23 Schering Corp Uso de anticuerpos biespecificos para ragular respuestas inmunes.
EP1530590A2 (fr) 2002-03-22 2005-05-18 Bioxell S.p.a. Nouveau recepteur trem (recepteur declencheur exprime sur les cellules myeloides) et utilisations correspondantes
AU2003242396A1 (en) 2002-05-24 2003-12-12 Takeda Pharmaceutical Company Limited Insulin resistance improving agents
US7388079B2 (en) 2002-11-27 2008-06-17 The Regents Of The University Of California Delivery of pharmaceutical agents via the human insulin receptor
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US9714282B2 (en) 2003-09-26 2017-07-25 Xencor, Inc. Optimized Fc variants and methods for their generation
GB0401730D0 (en) 2004-01-27 2004-03-03 Bioxell Spa Diagnosis method
PT2314620E (pt) * 2004-05-27 2013-09-02 Crucell Holland Bv Método de identificação de moléculas de ligação capazes de neutralizar o vírus da raiva
US7700099B2 (en) 2005-02-14 2010-04-20 Merck & Co., Inc. Non-immunostimulatory antibody and compositions containing the same
US8101345B1 (en) 2005-03-25 2012-01-24 Isis Pharmaceuticals, Inc. Proinflammatory nucleic acids
KR20060135280A (ko) 2005-06-24 2006-12-29 전남대학교산학협력단 선천성 면역에 관여하는 트렘-2의 클로닝
AU2006265113A1 (en) 2005-07-01 2007-01-11 The Johns Hopkins University Compositions and methods for the treatment or prevention of disorders relating to oxidative stress
US20070041905A1 (en) 2005-08-19 2007-02-22 Hoffman Rebecca S Method of treating depression using a TNF-alpha antibody
GEP20135917B (en) 2006-03-17 2013-09-10 Biogen Idec Inc Stabilized polypeptide compositions
DE202006007499U1 (de) 2006-05-11 2007-01-11 Osaka University Verwendung einer Zusammensetzung, die Plexin-A1-DAP12-Interaktion inhibiert, zur Behandlung von Entzündungs-, Autoimmun- oder Knochenresorptionserkrankungen
CN105837690A (zh) 2006-06-12 2016-08-10 新兴产品开发西雅图有限公司 具有效应功能的单链多价结合蛋白
CA2551163A1 (fr) 2006-07-17 2008-01-17 Boehringer Ingelheim International Gmbh Methodes pour le traitement de maladies inflammatoires, de maladies autoimmunes ou de maladies de resorption osseuse
US7553936B2 (en) 2006-12-04 2009-06-30 The United States of America as represented by Secretary Department of Health and Human Services Anti-TREM-like transcript-1 (TLT-1) antibodies and compositions
CN101687916A (zh) 2007-01-16 2010-03-31 惠氏公司 通过trem-1的炎症治疗、检测和监控
US8280711B2 (en) 2007-03-12 2012-10-02 ESBATech, an Alcon Biomedical Research Unit, LLC. Sequence based engineering and optimization of single chain antibodies
US8793074B2 (en) 2007-06-21 2014-07-29 Saint Louis University Sequence covariance networks, methods and uses therefor
CA2689941C (fr) 2007-06-25 2019-10-29 Esbatech Ag Methodes de modification d'anticorps et anticorps modifies presentant des proprietes fonctionnelles ameliorees
GR1007327B (el) 2007-08-08 2011-06-27 Ευαγγελος Γιαμαρελλος-Μπουρμπουλης Ο διαλυτος υποδοχεας ενεργοποιησης των μυελοκυτταρων (strem-1) ως δεικτης αποτελεσματικοτητας της θεραπειας του πεπτικου ελκους
US20100226925A1 (en) 2007-09-14 2010-09-09 Amgen Inc. Homogeneous Antibody Populations
TW200918553A (en) * 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
WO2009089004A1 (fr) 2008-01-07 2009-07-16 Amgen Inc. Méthode de fabrication de molécules hétérodimères fc d'anticorps utilisant les effets de conduite électrostatique
KR100960684B1 (ko) 2008-02-22 2010-05-31 전남대학교산학협력단 Ｇａ733-2 발현 억제제로서의 ｔｒｅｍ-2 유전자, 및 이를포함하는 형질전환 동물 및 이의 사용방법
WO2010045479A1 (fr) 2008-10-15 2010-04-22 The Board Of Trustees Of The University Of Illinois Compositions micellaires et liposomales de phospholipide et leurs utilisations
CA2759978C (fr) 2009-04-28 2020-06-02 Life & Brain Gmbh Procede permettant d'obtenir des cellules precurseurs microgliales humaines a partir de cellules souches pluripotentes
WO2010132370A2 (fr) 2009-05-11 2010-11-18 Government Of The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Peptides solubles de la famille trem-1 et procédés d'utilisation
RU2012101999A (ru) 2009-06-22 2013-07-27 МЕДИММЬЮН, ЭлЭлСи РЕКОМБИНАНТНЫЕ УЧАСТКИ Fc ДЛЯ САЙТ-СПЕЦИФИЧЕСКОЙ КОНЪЮГАЦИИ
US8513185B2 (en) 2009-10-13 2013-08-20 Alexander B. Sigalov Inhibition of TREM receptor signaling with peptide variants
CN102038698A (zh) 2009-10-14 2011-05-04 山东绿叶天然药物研究开发有限公司 莫诺苷的新用途
JO3244B1 (ar) * 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
CN102127168A (zh) 2010-01-19 2011-07-20 中国人民解放军第二军医大学 一种髓样细胞表达激发受体-1的重组融合蛋白及其应用
KR20110086460A (ko) 2010-01-22 2011-07-28 한국교원대학교산학협력단 수용성 수용체 라이브러리 및 이를 이용한 사이토카인 발현 조절 유전자의 스크리닝 방법
ES2805301T3 (es) 2010-04-08 2021-02-11 Inst Nat Sante Rech Med Péptidos inhibidores derivados del transcrito de tipo TREM-1 (TLT-1) y sus usos
CA2798120A1 (fr) 2010-04-30 2011-11-03 Paul P. Tamburini Anticorps dont l'antigenicite pour l'humain est reduite
WO2012016333A1 (fr) 2010-08-06 2012-02-09 University Health Network Biomarqueurs du paludisme
US20130130354A1 (en) 2010-09-28 2013-05-23 CTI Salud S.A. Novel genes and uses thereof, expression profile of colon, gastric and pancreatic cancer
UY33826A (es) 2010-12-22 2012-07-31 Abbott Lab Proteínas de unión con dominios trivariables y sus usos
UY33827A (es) 2010-12-22 2012-07-31 Abbott Lab Proteínas de unión a media-inmunoglobulina y sus usos
US10689447B2 (en) 2011-02-04 2020-06-23 Genentech, Inc. Fc variants and methods for their production
WO2012125495A2 (fr) 2011-03-11 2012-09-20 Amgen Inc. Procédé d'analyse mutationnelle corrélée pour améliorer des anticorps thérapeutiques
KR20120112973A (ko) 2011-04-04 2012-10-12 전남대학교산학협력단 비만 또는 제 2형 당뇨의 예방 또는 치료용 조성물
US20130058947A1 (en) 2011-09-02 2013-03-07 Stem Centrx, Inc Novel Modulators and Methods of Use
HRP20240230T1 (hr) 2011-10-11 2024-04-26 F. Hoffmann - La Roche Ag Poboljšani sklop bispecifičnih protutijela
AU2012325723A1 (en) 2011-10-21 2014-05-15 Stemgenics, Inc Functionalized nanoparticles for intracellular delivery of biologically active molecules
PT2773671T (pt) 2011-11-04 2021-12-14 Zymeworks Inc Geração de anticorpo heterodimérico estável com mutações no domínio fc
CN103906533A (zh) 2011-11-07 2014-07-02 米迪缪尼有限公司 多特异性和多价结合蛋白及其用途
EP2794653B1 (fr) 2011-12-23 2019-03-13 Pfizer Inc Régions constantes d'anticorps modifiés pour conjugaison spécifique à un site, et leurs procédés et utilisations
TWI450727B (zh) 2011-12-29 2014-09-01 Ind Tech Res Inst 抗人類輸鐵蛋白受體的單域抗體與其應用
CN102517287B (zh) 2012-01-10 2013-09-11 广西大学 抑制水牛TREM1基因表达的shRNA、慢病毒表达载体及其构建方法和应用
KR20130114951A (ko) 2012-04-10 2013-10-21 한양대학교 산학협력단 폴리감마글루탐산을 포함하는 Ｔｈ17 매개성 질환 예방 또는 치료용 조성물
CA2884121C (fr) 2012-09-07 2021-10-12 Inserm (Institut National De La Sante Et De La Recherche Medicale) Peptides inhibiteurs issus du transcrit 1 de type trem, recepteur de declenchement exprime sur des cellules myeloides 1 (trem-1), (tlt-1) et leurs utilisations
CA3139031A1 (fr) * 2012-10-04 2014-04-10 Dana-Farber Cancer Institute, Inc. Anticorps monoclonaux humains anti pd-l1 et procedes d'utilisation
CA2887825A1 (fr) 2012-10-23 2014-05-01 The Board Of Regents Of The University Of Texas System Anticorps avec des domaines fc d'igg modifies
WO2014074942A1 (fr) 2012-11-08 2014-05-15 Illumina, Inc. Variants de risque de développer la maladie d'alzheimer
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
US9066928B1 (en) * 2012-12-04 2015-06-30 University Of Kentucky Research Foundation Method, composition, and kit useful for treatment of alzheimer's disease
US9546203B2 (en) 2013-03-14 2017-01-17 Amgen Inc. Aglycosylated Fc-containing polypeptides with cysteine substitutions
IL242088B2 (en) 2013-05-20 2023-12-01 Genentech Inc Anti-transferrin receptor antibodies and methods of use
KR20150010326A (ko) 2013-07-19 2015-01-28 전남대학교산학협력단 비만 및 제 2형 당뇨 또는 지방간의 예방 또는 치료용 바이아릴아마이드를 포함한 유도체 화합물
CA2825821A1 (fr) 2013-08-28 2015-02-28 Chiesi Farmaceutici S.P.A. Derives d'acide 1-phenylalcane-carboxylique pour le traitement de la maladie d'alzheimer et la sclerose en plaques
KR101402921B1 (ko) 2013-08-28 2014-06-02 전남대학교산학협력단 비만 또는 제 2형 당뇨의 치료를 위한 레스베라톨 유도체의 이용
WO2015037000A1 (fr) 2013-09-11 2015-03-19 Compugen Ltd Polypeptides vstm5 et leurs utilisations en tant que médicament pour le traitement du cancer, de maladies infectieuses et de maladies de type immunitaire
CN103555829B (zh) 2013-10-12 2015-10-21 厦门人瑞生物医药科技有限公司 一种检测trem2基因r47h突变的探针、试剂盒和方法
WO2015103594A1 (fr) 2014-01-06 2015-07-09 Children's Medical Center Corporation Biomarqueurs pour une démence et des troubles neurologiques liés à la démence
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
CN103866041A (zh) 2014-04-04 2014-06-18 厦门大学 帕金森病和脑白质疏松症的突变检测试剂盒及其检测方法
AU2015243380B2 (en) 2014-04-11 2020-05-14 Medimmune, Llc Conjugated compounds comprising cysteine-engineered antibodies
CN105218669A (zh) 2014-06-10 2016-01-06 河北翰林生物科技有限公司 制备抗人r47h-trem2突变体的人单克隆抗体的方法
US20170218091A1 (en) 2014-07-03 2017-08-03 Abbvie Inc. Monovalent binding proteins
DK3172232T3 (da) 2014-07-17 2024-02-12 Novo Nordisk As Site directed mutagenesis of trem-1 antibodies for decreasing viscosity
IL279606B (en) 2014-08-08 2022-08-01 Alector Llc Anti-trem2 antibodies and methods of using them
KR101756417B1 (ko) 2014-08-21 2017-07-10 한국유나이티드제약 주식회사 금제제를 포함하는 간 섬유화 또는 간 경화의 예방 또는 치료용 약학적 조성물
WO2016049641A1 (fr) 2014-09-28 2016-03-31 The Regents Of The University Of California Modulation de cellules myeloïdes stimulatrices et non stimulatrices
WO2016064895A1 (fr) 2014-10-20 2016-04-28 The Brigham And Women's Hospital, Inc. Ciblage de l'apolipoprotéine e (apoe) dans une maladie neurologique
US10081792B2 (en) 2014-12-31 2018-09-25 Wisconsin Alumni Research Foundation Derivation of human microglia from pluripotent stem cells
PL3283508T3 (pl) 2015-04-17 2021-10-11 Alpine Immune Sciences, Inc. Białka immunomodulacyjne o dostrajalnym powinowactwie
EP3297632A4 (fr) 2015-05-18 2019-01-16 Synaptec Development LLC Clairance de galantamine d'amyloides
WO2016201389A2 (fr) 2015-06-12 2016-12-15 Alector Llc Anticorps anti-cd33 et leurs procédés d'utilisation
CA2988982A1 (fr) 2015-06-12 2016-12-15 Alector Llc Anticorps anti-cd33 et leurs procedes d'utilisation
US10765679B2 (en) 2015-07-04 2020-09-08 Emory University Use of TREM-1 inhibitors for treatment, elimination and eradication of HIV-1 infection
US20180194861A1 (en) 2015-07-10 2018-07-12 Abbvie Inc. IgM- or IgE-Modified Binding Proteins and Uses Thereof
DK3456346T3 (da) 2015-07-30 2021-08-30 Macrogenics Inc Pd-1- og lag-3-bindingsmolekyler og fremgangsmåder til anvendelse deraf
JP7525980B2 (ja) 2015-08-28 2024-07-31 アレクトル エルエルシー 抗Ｓｉｇｌｅｃ－７抗体及びその使用方法
WO2017058866A1 (fr) 2015-09-28 2017-04-06 Precision Immune, Inc. Anticorps anti-trem2 et leurs utilisations
CA2997960A1 (fr) 2015-10-06 2017-04-13 Alector Llc Anticorps anti-trem2 et leurs procedes d'utilisation
WO2017075432A2 (fr) 2015-10-29 2017-05-04 Alector Llc Anticorps anti-siglec-9 et leurs procédés d'utilisation
US20170218058A1 (en) 2016-01-28 2017-08-03 Alector, LLC Anti-apoe4 antigen-binding proteins and methods of use thereof
EP3442543A4 (fr) 2016-02-11 2020-01-22 The Johns Hopkins University Compositions et méthodes pour la neurogenèse
WO2017147509A1 (fr) 2016-02-25 2017-08-31 Marco Colonna Compositions comprenant de la trem2 et leurs procédés d'utilisation
JP7023853B2 (ja) 2016-03-04 2022-02-22 アレクトル エルエルシー 抗ｔｒｅｍ１抗体及びその使用方法
US10875919B2 (en) 2016-04-26 2020-12-29 Alector Llc Chimeric receptors and methods of use thereof
WO2017191274A2 (fr) 2016-05-04 2017-11-09 Curevac Ag Arn codant pour une protéine thérapeutique
JP2019522044A (ja) 2016-06-01 2019-08-08 ザ・ユニバーシティ・オブ・ヴァージニア・パテント・ファウンデーション 中枢神経系におけるリンパ管を調節するための方法及び組成物
WO2018015573A2 (fr) 2016-07-22 2018-01-25 Deutsches Zentrum Für Neurodegenerative Erkrankungen E.V. (Dzne) Modulateurs du clivage de trem2 et leurs utilisations
CN106244682B (zh) 2016-07-29 2019-11-26 中山大学 Trem-2基因在鉴别猪对蓝耳病毒易感性中的应用
CN106636330B (zh) 2016-09-21 2017-12-15 郁金泰 阿尔茨海默病的诊断和治疗药物
CA3040687A1 (fr) 2016-10-14 2018-04-19 Childrens' Medical Center Corporation Compositions et procedes pour le traitement de maladies ou de troubles du systeme nerveux central
KR102650524B1 (ko) 2016-12-09 2024-03-26 알렉터 엘엘씨 항-sirp-알파 항체 및 그의 사용 방법
US20200095280A1 (en) 2016-12-23 2020-03-26 Genervon Biopharmaceuticals Llc Methods of using GM6 in diagnosing and treating Alzheimers disease
CN110573167A (zh) 2017-01-12 2019-12-13 杜克大学 用于治疗脱髓鞘疾病的组合物和方法
EP3570883A2 (fr) 2017-01-17 2019-11-27 Yeda Research and Development Co. Ltd Procédés de traitement de maladies neurodégénératives par induction de cellules de microglie associées à une maladie (dam)
WO2018136598A1 (fr) 2017-01-18 2018-07-26 Evelo Biosciences, Inc. Méthodes de traitement du cancer
CA3049791A1 (fr) 2017-01-27 2018-08-02 Silverback Therapeutics, Inc. Conjugues ciblant les tumeurs et leurs methodes d'utilisation
US10143187B2 (en) 2017-02-17 2018-12-04 Denali Therapeutics Inc. Transferrin receptor transgenic models
WO2018157014A1 (fr) 2017-02-24 2018-08-30 Duke University Biomarqueurs métaboliques pour l'identification et la caractérisation de la maladie d'alzheimer
JP2020513794A (ja) 2017-02-28 2020-05-21 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 多能性幹細胞および造血始原細胞からのヒトミクログリア様細胞の分化と使用
US11957115B2 (en) 2017-03-21 2024-04-16 The Jackson Laboratory Genetically modified mouse expressing human APOE4 and mouse Trem2 p.R47H and methods of use thereof
KR101936249B1 (ko) 2017-04-04 2019-01-08 경희대학교 산학협력단 쿠마타케닌을 포함하는 암의 예방, 개선 또는 치료용 조성물
JOP20190248A1 (ar) 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
US20180318379A1 (en) 2017-05-01 2018-11-08 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of triggering receptor expressed on myeloid cells 1 (trem1) to treat central nervous system disorders
EP3625258A1 (fr) 2017-05-16 2020-03-25 Alector LLC Anticorps anti-siglec-5 et leurs procédés d'utilisation
CA3065999A1 (fr) 2017-05-24 2018-11-29 Nanosomix, Inc. Detection de biomarqueurs sur des vesicules pour le diagnostic et le pronostic de maladies et de troubles
MX2019014576A (es) 2017-06-05 2020-07-29 Janssen Biotech Inc Anticuerpos multiespecíficos manipulados genéticamente y otras proteínas multiméricas con mutaciones asimétricas en la región ch2-ch3.
JP7356970B2 (ja) 2017-06-25 2023-10-05 システィミューン， インク． 多重特異性抗体とその作製及び使用方法
CN109206503A (zh) 2017-07-07 2019-01-15 厦门大学 一种蛋白用于制备防治阿尔茨海默病药物的用途
US20190008812A1 (en) 2017-07-07 2019-01-10 Washington University Methods for treating microglial dysfunction
WO2019016784A1 (fr) 2017-07-21 2019-01-24 Universidade De Coimbra Anticorps anti-nucléoline
CN110945018A (zh) 2017-07-27 2020-03-31 诺华股份有限公司 抗脱落酶的trem2变体
PE20200148A1 (es) 2017-08-03 2020-01-17 Alector Llc Anticuerpos anti-trem2 y metodos para utilizarlos
CR20190486A (es) 2017-08-03 2020-02-10 Alector Llc Anti-cd33 antibodies and methods of use thereof
WO2019032624A1 (fr) 2017-08-08 2019-02-14 Pionyr Immunotherapeutics, Inc. Compositions et procédés pour désactiver des cellules méyloïdes exprimant trem1
JP7403441B2 (ja) 2017-09-14 2023-12-22 デナリ セラピューティクス インコーポレイテッド 抗ｔｒｅｍ２抗体及びその使用方法
US20200309788A1 (en) 2017-09-29 2020-10-01 The General Hospital Corporation Methods for identifying and treating adrenomyeloneuropathy (amn)
US11364303B2 (en) 2017-09-29 2022-06-21 Pfizer Inc. Cysteine engineered antibody drug conjugates
CN112553210B (zh) 2017-10-03 2024-09-24 普利维尔治疗公司 用于溶酶体障碍的基因疗法
WO2019079529A1 (fr) 2017-10-17 2019-04-25 The Translational Genomics Research Institute Agonistes de trem2 pour la stimulation de la microglie et des méthodes d'identification
US10597462B1 (en) 2017-11-08 2020-03-24 University Of Puerto Rico Anti-TLT-1 antibody and uses thereof
JP2021502977A (ja) 2017-11-15 2021-02-04 ユニバルシテ ラバル 神経学的状態、がん、細菌性感染症又はウイルス性感染症の治療及び／又は予防のためのｓｒｓｆ３作用剤の使用
CN109837330A (zh) 2017-11-28 2019-06-04 上海中优精准医疗科技股份有限公司 一种检测trem2基因多态性的探针及方法
US11470827B2 (en) 2017-12-12 2022-10-18 Alector Llc Transgenic mice expressing human TREM proteins and methods of use thereof
KR20200097765A (ko) 2017-12-12 2020-08-19 파이오니어 임뮤노테라퓨틱스, 인코퍼레이티드 항-trem2 항체 및 관련 방법
CN111971301A (zh) 2018-01-31 2020-11-20 艾莱克特有限责任公司 抗ms4a4a抗体及其使用方法
WO2019161080A1 (fr) 2018-02-14 2019-08-22 Yale University Compositions pour la modulation d'une protéine trem ou treml et procédés d'utilisation
NL2020520B1 (en) 2018-03-02 2019-09-12 Labo Bio Medical Invest B V Multispecific binding molecules for the prevention, treatment and diagnosis of neurodegenerative disorders
US20210000807A1 (en) 2018-03-22 2021-01-07 Nsc Therapeutics Gmbh Compounds and methods for use in the treatment of microglia-mediated disorders
EP3774902A1 (fr) 2018-04-02 2021-02-17 Bristol-Myers Squibb Company Anticorps anti-trem-1 et utilisations associées
JP2021521122A (ja) 2018-04-09 2021-08-26 ザ ジェネラル ホスピタル コーポレイション 筋萎縮性側索硬化症および関連障害の治療のための併用療法
US11319373B2 (en) 2018-05-25 2022-05-03 Alector Llc Anti-SIRPA antibodies and methods of use thereof
MA52764A (fr) 2018-06-08 2021-04-28 Alector Llc Anticorps anti-siglec-7 et leurs méthodes d'utilisation
CN108752482B (zh) 2018-06-12 2019-04-30 南京卡提医学科技有限公司 携带截短或未截短的髓样细胞触发性受体信号结构的嵌合抗原受体及其应用
WO2019246483A1 (fr) 2018-06-21 2019-12-26 The Jackson Laboratory Modèles de souris génétiquement modifiée de la maladie d'alzheimer
BR112020026819A2 (pt) 2018-06-29 2021-04-20 Alector Llc anticorpos isolados, ácido nucleico, vetor, células hospedeiras, método de produção de um anticorpo, composição farmacêutica, métodos para tratar o câncer e para tratar uma doença e usos de um anticorpo
US11278575B2 (en) 2018-07-12 2022-03-22 Duke University Compositions and methods for the treatment of demyelinating conditions
JP2021531751A (ja) 2018-07-12 2021-11-25 コーバス・ファーマシューティカルズ・インコーポレイテッド アデノシン経路活性化を有する癌を検出および治療するための方法
US20210311076A1 (en) 2018-07-16 2021-10-07 University Of Virginia Patent Foundation Compositions and methods of diagnosis and treatment for neurological diseases
CN109112214A (zh) 2018-07-27 2019-01-01 复旦大学附属中山医院 模式识别受体trem2在肝癌预后和治疗中的应用
US20210395361A1 (en) 2018-07-27 2021-12-23 Alector Llc Anti-siglec-5 antibodies and methods of use thereof
CR20210155A (es) 2018-08-31 2021-05-10 Alector Llc Anticuerpos anti-cd33 y métodos para usarlos
US20220218652A1 (en) 2018-09-05 2022-07-14 The General Hospital Corporation Methods of treating cytokine release syndrome
JP2022500081A (ja) 2018-09-11 2022-01-04 ワシントン・ユニバーシティWashington University 抗ｔｒｅｍ−２アゴニスト抗体
US20210315816A1 (en) 2018-09-12 2021-10-14 Board Of Regents Of The University Of Nebraska Antimicrobial compositions and methods
MX2021003577A (es) 2018-09-28 2021-08-24 Inotrem Uso de niveles trem-1 soluble para identificar sujetos susceptibles de responder a una terapia antiinflamatoria.
KR102096282B1 (ko) 2018-10-15 2020-04-02 재단법인대구경북과학기술원 재조합 베큘로바이러스를 이용한 인간 ｔｒｅｍ２ 세포막 단백질의 효율적인 정제방법
UY38407A (es) 2018-10-15 2020-05-29 Novartis Ag Anticuerpos estabilizadores de trem2
KR102156165B1 (ko) 2018-10-29 2020-09-15 재단법인대구경북과학기술원 인간 ｔｒｅｍ２ 세포막 단백질에 대한 단일클론항체, 이를 생산하는 하이브리도마 세포주 및 이의 용도
CN111135185A (zh) 2018-11-02 2020-05-12 杭州星鳌生物科技有限公司 天然免疫激活通过调控髓系细胞触发受体trem2抑制大脑神经慢性炎症
EP3876956A4 (fr) 2018-11-08 2022-12-28 The Regents of The University of California Systèmes et procédés de ciblage de cellules cancéreuses
MA54296A (fr) 2018-11-26 2021-10-06 Denali Therapeutics Inc Procédés de traitement du métabolisme lipidique dérégulé
US20220127356A1 (en) 2018-12-10 2022-04-28 Mor Research Applications Trem2 antibodies and uses thereof
WO2020132230A2 (fr) 2018-12-20 2020-06-25 Genentech, Inc. Fc d'anticorps modifiés et méthodes d'utilisation
CN109646668B (zh) 2019-01-04 2019-10-18 厦门大学 一种多肽用于制备防治阿尔茨海默病药物的用途
US20220089768A1 (en) 2019-01-04 2022-03-24 Trio Pharmaceuticals, Inc. Multi-specific protein molecules and uses thereof
MA54752A (fr) 2019-01-14 2021-11-24 Univ Virginia Patent Foundation Utilisation d'inhibiteurs d'intégrine pour le traitement ou la prévention d'un trouble immunitaire neurologique et/ou d'une lésion du système nerveux
US20220104468A1 (en) 2019-01-22 2022-04-07 St. Jude Children's Research Hospital Modulation of lc3-associated endocytosis pathway and genetically modified non-human animals as a model of neuroinflammation and neurodegeneration
EP3914071A4 (fr) 2019-01-23 2022-10-19 The Regents of the University of California Cellules rapporteurs de construction génomique humaine et modèles de souris pour cribler des agents thérapeutiques contre des gènes associés à une maladie exprimée par la microglie
EP3917623A4 (fr) 2019-02-01 2022-10-19 Avrobio, Inc. Compositions et méthodes pour le traitement de troubles neurocognitifs
WO2020160217A1 (fr) 2019-02-01 2020-08-06 Seattle Children's Hospital (dba Seattle Children's Research Institute) Capteurs de microenvironnement pour réguler l'expression génique modifiée
MA54880A (fr) 2019-02-01 2021-12-08 Avrobio Inc Compositions et procédés de traitement de troubles neurocognitifs
WO2020172457A1 (fr) 2019-02-20 2020-08-27 Denali Therapeutics Inc. Anticorps anti-trem2 et leurs procédés d'utilisation
WO2020194317A1 (fr) 2019-03-28 2020-10-01 Yeda Research And Development Co. Ltd. Méthode de traitement de troubles liés aux lipides
CN110320368A (zh) 2019-05-30 2019-10-11 广州医科大学附属第一医院（广州呼吸中心） 基于trem2的诊断试剂盒及其在帕金森病诊断产品上的应用
CN110241208A (zh) 2019-08-02 2019-09-17 辽宁中医药大学 Trem2作为早期诊断冠心病的分子标志物的应用
CN110511240B (zh) 2019-08-27 2022-03-08 南京医科大学 一种髓细胞触发受体2的内源性配体及其应用
CN110882262A (zh) 2019-11-06 2020-03-17 南京医科大学 一种髓细胞触发受体2的激活用药及其应用
WO2021101823A1 (fr) 2019-11-22 2021-05-27 Eli Lilly And Company Anticorps trem2 et leurs utilisations
JP2023505279A (ja) 2019-12-05 2023-02-08 アレクトル エルエルシー 抗ｔｒｅｍ２抗体の使用方法
CN111184742B (zh) 2020-02-13 2022-06-24 中山大学附属第五医院 Trem-2+t细胞在制备用于治疗结核病药物中的应用

Also Published As

Publication number Publication date
CN110709100A (zh) 2020-01-17
US20210054069A1 (en) 2021-02-25
KR20200018778A (ko) 2020-02-20
US20220204611A1 (en) 2022-06-30
MX2024000156A (es) 2024-01-23
AU2022221560A1 (en) 2022-09-22
AU2018254600A1 (en) 2019-10-24
CL2019003000A1 (es) 2020-02-14
JP7252134B2 (ja) 2023-04-04
TWI812619B (zh) 2023-08-21
WO2018195506A1 (fr) 2018-10-25
JP2022188272A (ja) 2022-12-20
AU2018254600B2 (en) 2022-05-26
CO2019012998A2 (es) 2020-02-18
EP3612218A1 (fr) 2020-02-26
UY37698A (es) 2018-10-31
EP3612218A4 (fr) 2021-07-28
JOP20190248A1 (ar) 2019-10-20
CR20210171A (es) 2021-05-21
SG11201909646TA (en) 2019-11-28
CR20190525A (es) 2020-03-20
TW202423975A (zh) 2024-06-16
PH12019502356A1 (en) 2020-12-07
TW201906628A (zh) 2019-02-16
US11186636B2 (en) 2021-11-30
CA3060409A1 (fr) 2018-10-25
JP7559025B2 (ja) 2024-10-01
BR112019021991A2 (pt) 2020-06-16
PE20200485A1 (es) 2020-03-03
JP2020517249A (ja) 2020-06-18
MX2019012364A (es) 2019-11-28

Similar Documents

Publication Publication Date Title
MA52273A (fr) Protéines de liaison à un antigène anti-trem2 et leurs utilisations
MA44885A (fr) Protéines de liaison bispécifiques et leurs utilisations
MA44060A (fr) Protéines de liaison à un antigène bispécifiques anti-tl1a/anti-tnf-alpha et leurs utilisations
MA42808A (fr) Anticorps de liaison à l'il-8 et leurs utilisations
MA49683A (fr) Anticorps anti-cd8 et leurs utilisations
MA54555A (fr) Agonistes de glp-1r et leurs utilisations
DK3383916T3 (da) Anti-CD73-antistoffer og anvendelser deraf
MA46471A (fr) Protéines actriib à variant et leurs utilisations
MA49687A (fr) Anticorps anti-ctla-4 et leurs utilisations
MA42821A (fr) Protéines de liaison à l'antigène tétraspécifiques et bispécifiques tétravalentes et utilisations de celles-ci
MA42622A (fr) Agents de liaison à tigit et leurs utilisations
MA47789A (fr) Anticorps anti-phf-tau et leurs utilisations
MA43576A (fr) Anticorps anti-lag3 et fragments de fixation à l'antigène
MA49537A (fr) Anticorps anti-lag3 et leurs utilisations
MA45235A (fr) Anticorps anti-c5 et leurs utilisations
MA50618A (fr) Polyrhérapies et leurs utilisations
MA44986A (fr) Protéines de fusion gdf15 et leurs utilisations
MA41460A (fr) Agents de liaison à la tnfrsf et leurs utilisations
DK3710484T3 (da) Ctla-4-bindende antistoffer og anvendelser deraf
MA53883A (fr) Protéines de fusion de récepteur type i et type ii à bras unique et leurs utilisations
MA47113A (fr) Protéines de liaison à l'antigène anti- neuropiline et leurs méthodés d'utilisation
MA55347A (fr) Anticorps anti-lag3 et fragments de fixation à l'antigène
MA49886A (fr) Anticorps anti-par2 et leurs utilisations
MA42059A (fr) Agents de liaison bispécifique à l'antigène membranaire spécifique de la prostate (psma) et utilisations de ceux-ci
MA41313A (fr) Anticorps de liaison de la protéine april modifiés